Gastro Medical News about Crohn Disease Methotrexate

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Use of Antiemetic Agents in Acute Gastroenteritis

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Methotrexate for maintenance of remission in Crohn's disease
Cochrane Reviews, 10/27/09

Patel V et al. – This review shows that methotrexate (15 mg/week) injected intramuscularly (i.e. into muscles located in the arm or thigh) for 40 weeks is an effective treatment for preventing relapse (return of disease symptoms) among patients whose disease became inactive while taking higher doses of intramuscular methotrexate (25 mg/week). Side effects occurred in a small number of patients. These side effects are usually mild in nature and include nausea and vomiting, cold symptoms, abdominal pain, headache, joint pain and fatigue. Methotrexate (12.5 to 15 mg/week) taken orally has not been shown to be effective treatment for inactive Crohn's disease. However, there has been little study of this approach.

<< Previous
Interventions for dysphagia in oesophageal cancer

Next >>
Interventions for prevention of post-operative recurrence of...

A Case-Control Study on Risk Factors of Osteoporosis in Patients with Crohn's Disease
Archives of Iranian Medicine, 11/13/09 Relevance Score: 69%

Gastrointestinal stromal tumor causing small bowel intussusception in a patient with Crohn's disease
World Journal of Gastroenterology, 11/13/09 Relevance Score: 69%

Campylobacter concisus and other Campylobacter species in children with newly diagnosed Crohns disease
Inflammatory Bowel Disease, 11/05/09 Relevance Score: 69%

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: A randomised phase 2 trial
The Lancet, 11/05/09 Relevance Score: 69%

C-Reactive Protein and Disease Activity in Children with Crohns Disease
Digestive Diseases and Sciences, 10/26/09 Relevance Score: 69%